 The investigators are registering all biopsy-proven primary IgA nephropathy IgAN patients at recruited hospitals and developing a IgAN database in China. Patients will be follow-up every one year, and both baseline and follow-up information will be entered into the registration system. All-cause and cardiovascular mortality and a composite renal outcome of doubling of serum creatinine and end stage renal failure ESRD, defined as initiation of dialysis or kidney transplantation of IgAN patients will be compared using the IgAN database. 